Citi analyst David Lebowitz opened a "negative Catalyst Watch" on shares of Blueprint Medicines given a view that the Ayvakit response data in February will likely add to doubts regarding the size of the market opportunity. Citi views the Ayvakit application for indolent systemic mastocytosis as being approvable but says questions regarding the size of the opportunity persist.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BPMC:
- Blueprint Medicines’ Supplemental NDA for Ayvakit approved by FDA
- Wells Fargo upgrades Blueprint Medicines to Equal Weight with $41 price target
- Blueprint Medicines upgraded to Equal Weight from Underweight at Wells Fargo
- Blueprint Medicines initiated with a Buy at Needham
- Blueprint Medicines price target lowered to $53 from $58 at Barclays
